IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, today announced that it has received its first purchase order for
InnovoSCEPT(TM) veterinary biofilm susceptibility tests for launch into the
Japanese veterinary market. The Company anticipates expansion to the balance of
the worldwide veterinary market to follow quickly. 


"This initial order of InnovoSCEPT(TM) veterinary tests provides a new and
improved method to identify effective treatments for chronic infections in
animals. The situation in the animal world parallels what is seen in human
health, where inappropriate treatment of chronic infections results in
unnecessary patient suffering, repeated treatment failures, increased health
care costs and an increase in the potential for bacterial resistance," said Ken
Boutilier, President and CEO of Innovotech. "Our company has developed the
InnovoSCEPT(TM) line of five new products for susceptibility testing in both
humans and animals in less than six months. This initial purchase order for
introduction into the Japanese market is just the start of what should become an
important revenue generator." 


The InnovoSCEPT(TM) line of veterinary tests, based on the technology used to
develop Innovotech's bioFILM PA(TM) human susceptibility test, will assist
veterinarians in the selection of the most effective antibiotic treatment of
infections caused by both gram-positive and gram-negative bacteria in both small
and large animals. As with human infections, many common disease-causing
bacteria exist in animals as biofilms, such as those responsible for infections
causing mastitis in dairy cows or persistent skin infections in family pets.
These chronic infections are often difficult to eradicate and Innovotech's tests
have a much better chance of being successful in the identification of the best
treatment approach in comparison to current methods.


Biofilms are organized communities of microorganisms that exist in virtually
every natural environment. Biofilms can be up to 1000 times more resistant to
treatment than the same organism in a free-floating state.


About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
for a host of diseases both in human health and agriculture due to their
inherent resistance to existing antibiotics and disinfectants. Aside from
Innovotech's products there are no antibiotics, disinfectants, diagnostics or
regulatory standards designed specifically for biofilm-forming organisms. 


Innovotech has a broad range of products that address the issue of biofilms
within a number of different industries, including three commercial products,
the MBEC Assay(TM), bioFILM PA(TM) and InnovoSCEPT(TM) veterinary kits. The MBEC
Assay(TM) is a high throughput biofilm growth device that was recently approved
as an ASTM International standard. bioFILM PA(TM) is the first diagnostic kit to
assist physicians in the selection of the most effective combination antibiotic
treatment of patients with biofilm-based chronic lung infections, while the
InnovoSCEPT(TM) veterinary kits are designed to determine the most effective
antibiotic treatment for infections in both large and small animals. 


Innovotech also has two products in advanced stages of development; Agress(R) is
a unique, environmentally friendly seed treatment and plant spray designed to
protect crops against both bacterial and fungal infections and Sani-Lux(TM) is a
light-activated, natural hard surface sanitizer.


Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter:www.twitter.com/innovotech

Facebook:www.facebook.com/innovotech

This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024